Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HTMC0435 plus platinum and etoposide in extensive-stage small cell lung cancer
ChiCTR2500100955Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of HTMC0435 in small cell lung cancer (SCLC) (3 cohorts), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoints: Dose-limiting toxicity, Adverse events and 2 more. Started Apr 2025; status: recruiting.
02
Drugs
HTMC0435
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2500100955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500100955.